|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Elastography-based screening for esophageal varices in patients with advanced chronic liver disease显示文摘Elastography-based liver stiffness measurement(LSM) is a non-invasive tool for estimating liver fibrosis but also provides an estimate for the severity of portal hypertension in patients with advanced chronic liver disease(ACLD). The presence of varices and especially of varices needing treatment(VNT) indicates distinct prognostic stages in patients with compensated ACLD(cACLD). The Baveno VI guidelines suggested a simple algorithm based on LSM < 20 kPa(by transient elastography, TE) and platelet count > 150 G/L for ruling-out VNT in patients with cACLD. These(and other) TE-based LSM cut-offs have been evaluated for VNT screening in different liver disease etiologies. Novel point shear-wave elastography(pSWE) and two-dimensional shear wave elastography(2D-SWE) methodologies for LSM have also been evaluated for their ability to screen for 'any' varices and for VNT. Finally, the measurement of spleen stiffness(SSM) by elastography(mainly by pSWE and 2D-SWE) may represent another valuable screening tool for varices. Here, we summarize the current literature on elastography-based prediction of 'any' varices and VNT. Finally,we have summarized the published LSM and SSM cut-offs in clinically useful scale cards. | Rafael Paternostro Thomas Reiberger Theresa Bucsics | 2019 | World Journal of Gastroenterology2019，25，3： | 20 |
| 2 | Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis显示文摘Portal hypertension(PH),a common complication of liver cirrhosis,results in development of esophageal varices.When esophageal varices rupture,they cause significant upper gastrointestinal bleeding with mortality rates up to 20%despite state-of-the-art treatment.Thus,prophylactic measures are of utmost importance to improve outcomes of patients with PH.Several high-quality studies have demonstrated that non-selective beta blockers(NSBBs)or endoscopic band ligation(EBL)are effective for primary prophylaxis of variceal bleeding.In secondary prophylaxis,a combination of NSBB+EBL should be routinely used.Once esophageal varices develop and variceal bleeding occurs,standardized treatment algorithms should be followed to minimize bleeding-associated mortality.Special attention should be paid to avoidance of overtransfusion,early initiation of vasoconstrictive therapy,prophylactic antibiotics and early endoscopic therapy.Pre-emptive transjugular intrahepatic portosystemic shunt should be used in all Child C10-C13 patients experiencing variceal bleeding,and potentially in Child B patients with active bleeding at endoscopy.The use of carvedilol,safety of NSBBs in advanced cirrhosis(i.e.with refractory ascites)and assessment of hepatic venous pressure gradient response to NSBB is discussed.In the present review,we give an overview on the rationale behind the latest guidelines and summarize key papers that have led to significant advances in the field. | Nikolaus Pfisterer Lukas W Unger Thomas Reiberger | 2021 | World Journal of Hepatology2021，13，7： | 11 |
| 3 | Gut-liver axis signaling in portal hypertension显示文摘Portal hypertension(PHT)in advanced chronic liver disease(ACLD)results from increased intrahepatic resistance caused by pathologic changes of liver tissue composition(structural component)and intrahepatic vasoconstriction(functional component).PHT is an important driver of hepatic decompensation such as development of ascites or variceal bleeding.Dysbiosis and an impaired intestinal barrier in ACLD facilitate translocation of bacteria and pathogen-associated molecular patterns(PAMPs)that promote disease progression via immune system activation with subsequent induction of proinflammatory and profibrogenic pathways.Congestive portal venous blood flow represents a critical pathophysiological mechanism linking PHT to increased intestinal permeability:The intestinal barrier function is affected by impaired microcirculation,neoangiogenesis,and abnormal vascular and mucosal permeability.The close bidirectional relationship between the gut and the liver has been termed“gut-liver axis”.Treatment strategies targeting the gut-liver axis by modulation of microbiota composition and function,intestinal barrier integrity,as well as amelioration of liver fibrosis and PHT are supposed to exert beneficial effects.The activation of the farnesoid X receptor in the liver and the gut was associated with beneficial effects in animal experiments,however,further studies regarding efficacy and safety of pharmacological FXR modulation in patients with ACLD are needed.In this review,we summarize the clinical impact of PHT on the course of liver disease,discuss the underlying pathophysiological link of PHT to gut-liver axis signaling,and provide insight into molecular mechanisms that may represent novel therapeutic targets. | Benedikt Simbrunner Mattias Mandorfer Michael Trauner Thomas Reiberger | 2019 | World Journal of Gastroenterology2019，25，39： | 6 |
| 4 | Nonselective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis显示文摘 | T. Reiberger A. Ferlitsch B.A. Payer M. Mandorfer B.B. Heinisch H. Hayden F. Lammert M. Trauner M. Peck-Radosavljevic H. Vogelsang | 2012 | Journal of Hepatology2012，，： | 5 |
| 5 | Non-selective β Blockers Increase Risk for Hepatorenal Syndrome and Death in Patients with Cirrhosis and Spontaneous Bacterial Peritonitis显示文摘 | Mattias Mandorfer Simona Bota Philipp Schwabl Theresa Bucsics Nikolaus Pfisterer Matthias Kruzik Michael Hagmann Alexander Blacky Arnulf Ferlitsch Wolfgang Sieghart Michael Trauner Markus Peck-Radosavljevic Thomas Reiberger | 2014 | Gastroenterology2014，，： | 3 |
| 6 | Five‐year on‐treatment efficacy of lamivudine‐, tenofovir‐ and tenofovir + emtricitabine‐based HAART in HBV–HIV‐coinfected patients显示文摘 | L. Kosi T. Reiberger B. A. Payer K. Grabmeier‐Pfistershammer R. Strassl A. Rieger M. Peck‐Radosavljevic | 2012 | Journal of Viral Hepatitis2012，，11： | 2 |
| 7 | Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol显示文摘 | Thomas Reiberger Gregor Ulbrich Arnulf Ferlitsch Berit Anna Payer Philipp Schwabl Matthias Pinter Birgit B Heinisch Michael Trauner Ludwig Kramer Markus Peck-Radosavljevic | 2013 | Gut2013，，11： | 2 |
| 8 | Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis显示文摘 | Monika Ferlitsch Thomas Reiberger Matthias Hoke Petra Salzl Bernadette Schwengerer Gregor Ulbrich Berit Anna Payer Michael Trauner Markus Peck‐Radosavljevic Arnulf Ferlitsch | 2012 | Hepatology2012，，4： | 2 |
| 9 | Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic pa- tients with haemodynamic non-response to propranolol显示文摘 | Reiberger T Ulbrich G Ferlitsch A | 2013 | Gut2013，62，11： | 1 |
| 10 | The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma-a pilot study显示文摘 | Pinter M Sieghart W Reiberger T | 2012 | Aliment Pharmacol Ther2012，35，1： | 1 |
| 11 | Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats显示文摘 | Thomas Reiberger Bernhard Angermayr Philipp Schwabl Natascha Rohr-Udilova Markus Mitterhauser Alfred Gangl Markus Peck-Radosavljevic | 2009 | Journal of Hepatology2009，，5： | 1 |
| 12 | Sor- afenib attenuates the portalhypertensive syndrome in partial portal vein ligated rats 显示文摘 | REIBERGER T ANGERMAYR B SCHWABL P | 2009 | Hepatol2009，51，： | 1 |
| 13 | An orthotopic mouse model of hepatocellular carcinoma with underlying liver cirrhosis 显示文摘 | Reiberger T Chen Y Ramjiawan RR | 2015 | Nat Protoc2015，10，8： | 1 |
| 14 | Aqueous surfactant systems for oil recovery显示文摘 | Hill H J Reiberg J Stegemeier G L | 1973 | Journal of petroleum technology1973，25，2： | 1 |
| 15 | Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol显示文摘 | REIBERGER T ULBRICH G FERLITSCH A | 2013 | Gut2013，62，11： | 1 |
| 16 | Sorafenib at- tenuates the portalhypertensive syndrome in partial portal vein ligated rats 显示文摘 | Reiberger T Angermayr B Schwabl P | 2009 | Hepatol2009，51，5： | 1 |
| 17 | Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats 显示文摘 | Reiberger T Angermayr B Schwabl P | 2009 | J Hepatol2009，51，5： | 1 |
| 18 | Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol显示文摘 | Thomas Reiberger Gregor Ulbrich Arnulf Ferlitsch Berit Anna Payer Philipp Schwabl Matthias Pinter Birgit B Heinisch Michael Trauner Ludwig Kramer Markus Peck-Radosavljevic | 2013 | Gut2013，，11： | 1 |
| 19 | Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient显示文摘 | Payer BA Reiberger T Rutter K | 2010 | J Clin Virol2010，49，2： | 1 |
| 20 | The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma-a pilot study 显示文摘 | Pinter M Sieghart W Reiberger T | 2012 | Aliment Pharmacol Ther2012，35，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员